Key Points
- Casdin Partners Master Fund, L (reported as a director) bought 7,550,000 shares of Standard BioTools at $1.30 each on Nov 25, a $9,815,000 purchase that raised its holding to 71,750,000 shares (an 11.76% increase).
- The fund made a string of purchases from Nov 10–24 totaling 3,100,000 shares, bringing the disclosed November haul to about 10.65 million shares purchased for roughly $13.65 million.
- For context, Standard BioTools has a market cap of about $549.9M, a negative P/E, an analyst consensus of “Reduce” with an average target of $1.35, and a 1‑year price range of $0.92–$2.25.
Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) Director Casdin Partners Master Fund, L acquired 150,000 shares of the company's stock in a transaction that occurred on Monday, November 24th. The shares were acquired at an average cost of $1.43 per share, for a total transaction of $214,500.00. Following the completion of the transaction, the director directly owned 64,200,000 shares of the company's stock, valued at $91,806,000. The trade was a 0.23% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.
Casdin Partners Master Fund, L also recently made the following trade(s):
- On Tuesday, November 25th, Casdin Partners Master Fund, L purchased 7,550,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.30 per share, for a total transaction of $9,815,000.00.
- On Thursday, November 20th, Casdin Partners Master Fund, L acquired 450,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.30 per share, with a total value of $585,000.00.
- On Wednesday, November 19th, Casdin Partners Master Fund, L bought 350,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.28 per share, for a total transaction of $448,000.00.
- On Tuesday, November 18th, Casdin Partners Master Fund, L bought 275,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.23 per share, with a total value of $338,250.00.
- On Monday, November 17th, Casdin Partners Master Fund, L purchased 225,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.22 per share, for a total transaction of $274,500.00.
- On Friday, November 14th, Casdin Partners Master Fund, L acquired 250,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.24 per share, with a total value of $310,000.00.
- On Thursday, November 13th, Casdin Partners Master Fund, L bought 450,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $540,000.00.
- On Wednesday, November 12th, Casdin Partners Master Fund, L purchased 375,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $1.19 per share, with a total value of $446,250.00.
- On Tuesday, November 11th, Casdin Partners Master Fund, L acquired 300,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.20 per share, for a total transaction of $360,000.00.
- On Monday, November 10th, Casdin Partners Master Fund, L purchased 275,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.17 per share, for a total transaction of $321,750.00.
Standard BioTools Price Performance
LAB opened at $1.43 on Thursday. The company has a 50 day simple moving average of $1.29 and a two-hundred day simple moving average of $1.24. The firm has a market cap of $549.93 million, a P/E ratio of -4.47 and a beta of 1.25. Standard BioTools Inc. has a 1-year low of $0.92 and a 1-year high of $2.25.
Institutional Investors Weigh In On Standard BioTools
Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Standard BioTools by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 17,225,250 shares of the company's stock worth $18,603,000 after purchasing an additional 69,104 shares during the last quarter. Pacific Capital Partners Ltd purchased a new stake in Standard BioTools during the first quarter valued at approximately $1,701,000. XTX Topco Ltd purchased a new position in Standard BioTools in the first quarter worth $171,000. Rhumbline Advisers increased its position in shares of Standard BioTools by 11.4% during the first quarter. Rhumbline Advisers now owns 412,761 shares of the company's stock worth $446,000 after purchasing an additional 42,247 shares in the last quarter. Finally, Long Focus Capital Management LLC purchased a new stake in shares of Standard BioTools during the 1st quarter valued at $7,236,000. Hedge funds and other institutional investors own 53.74% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on LAB shares. Weiss Ratings restated a "sell (d-)" rating on shares of Standard BioTools in a research report on Wednesday, October 8th. Wall Street Zen cut Standard BioTools from a "hold" rating to a "strong sell" rating in a report on Saturday, November 8th. TD Cowen lowered their price target on Standard BioTools from $1.55 to $1.35 and set a "hold" rating for the company in a research report on Wednesday, November 5th. Finally, Cowen lowered shares of Standard BioTools from a "buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Standard BioTools has an average rating of "Reduce" and an average price target of $1.35.
View Our Latest Analysis on LAB
Standard BioTools Company Profile
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
